The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Systematic Review and Meta-Analysis

被引：30
作者：
Lockhart, I. A. [1 ]
Orme, M. E. [2 ]
Mitchell, S. A. [3 ]
机构：
[1] Pfizer Ltd, Walton Oaks Dorking Rd,Walton Hill, Tadworth KT20 7NS, England
[2] ICERA Consulting Ltd, Swindon, Wilts, England
[3] Abacus Int, Bicester, Oxon, England
来源：
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA | 2011年 / 1卷 / 01期
关键词：
Alzheimer disease; Behavioural/psychiatric symptoms of dementia; Behavioural medicine; Community Mental Health Services; Geriatric psychiatry; Home nursing; Meta-analysis; Preventive psychiatry; Systematic reviews;
D O I：
10.1159/000330032
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. Results: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI -3.51, 95% confidence interval (CI) -5.75, -1.27], whereas this was not the case for memantine (WMD -1.65, 95% CI -4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (-1.86, 95% CI -5.71, 1.99; p = 0.34). Conclusion: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码：212 / 227
页数：16
相关论文
共 52 条
  • [1] Alzheimer's Disease International, WORLD ALZH REP 2010
  • [2] Bakchine S, 2008, J ALZHEIMERS DIS, V13, P97
  • [3] Management of agitation and aggression associated with Alzheimer disease
    Ballard, Clive G.
    Gauthier, Serge
    Cummings, Jeffrey L.
    Brodaty, Henry
    Grossberg, George T.
    Robert, Philippe
    Lyketsos, Constantine G.
    [J]. NATURE REVIEWS NEUROLOGY, 2009, 5 (05) : 245 - 255
  • [4] Bentham P, 2004, LANCET, V363, P2105
  • [5] Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub3, 10.1002/14651858.CD001190.pub2]
  • [6] Donepezil preserves cognition and global function in patients with severe Alzheimer disease
    Black, S. E.
    Doody, R.
    Li, H.
    McRae, T.
    Jambor, K. M.
    Xu, Y.
    Sun, Y.
    Perdomo, C. A.
    Richardson, S.
    [J]. NEUROLOGY, 2007, 69 (05) : 459 - 469
  • [7] The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
    Bucher, HC
    Guyatt, GH
    Griffith, LE
    Walter, SD
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (06) : 683 - 691
  • [8] Campbell N, 2008, CLIN INTERV AGING, V3, P719
  • [9] PREDICTORS OF INSTITUTIONALIZATION AMONG CAREGIVERS OF PATIENTS WITH ALZHEIMERS-DISEASE
    COLERICK, EJ
    GEORGE, LK
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1986, 34 (07) : 493 - 498
  • [10] Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Cummings, Jeffrey L.
    Schneider, Eugene
    Tariot, Pierre N.
    Graham, Stephen M.
    [J]. NEUROLOGY, 2006, 67 (01) : 57 - 63
123456